购物车
- 全部删除
- 您的购物车当前为空
Venadaparib (NOV140101) 是一种选择性和具有口服活性的 PARP 抑制剂,对 PARP1和 PARP2的 IC50分别为 1.4 和 1.0 nM。它可防止 DNA 单链断裂 (SSB) 的修复,可研究实体瘤。
Venadaparib (NOV140101) 是一种选择性和具有口服活性的 PARP 抑制剂,对 PARP1和 PARP2的 IC50分别为 1.4 和 1.0 nM。它可防止 DNA 单链断裂 (SSB) 的修复,可研究实体瘤。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 425 | 现货 | |
2 mg | ¥ 612 | 现货 | |
5 mg | ¥ 936 | 现货 | |
10 mg | ¥ 1,490 | 现货 | |
25 mg | ¥ 2,990 | 现货 | |
50 mg | ¥ 4,390 | 现货 | |
100 mg | ¥ 6,290 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 997 | 现货 |
产品描述 | Venadaparib (NOV140101) (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib is insensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSBs) and can be used in solid tumor research. |
靶点活性 | PARP1:0.5 nM(EC50), PARP1/PARP2:1.4 nM/1.0 nM |
体外活性 | Venadaparib significantly inhibits PARP1-mediated PAR expression with an EC50?of 0.5 nM In DNA damage-induced Hela cells[1]. |
体内活性 | Oral administration of Venadaparib significantly inhibits PAR(>90%) in tumor tissues until 24 hr post-dose in the germline BRCA1-mutated ovarian cancer PDX model. Venadaparib also dose-dependently inhibits potent tumor growth compared to the Olaparib treatment group[1]. |
别名 | NOV140101, IDX-1197 |
分子量 | 406.45 |
分子式 | C23H23FN4O2 |
CAS No. | 1681017-83-3 |
Smiles | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CC(CNC2CC2)C1 |
密度 | 1.43 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 90 mg/mL (221.43 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容